Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down to $15.01

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $15.01, but opened at $14.56. Capricor Therapeutics shares last traded at $16.04, with a volume of 1,971,364 shares.

Analyst Upgrades and Downgrades

Several research analysts have commented on CAPR shares. Maxim Group raised their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a research report on Friday, September 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Capricor Therapeutics Trading Up 14.9 %

The stock’s 50-day moving average price is $5.21 and its 200-day moving average price is $5.42. The company has a market capitalization of $551.64 million, a P/E ratio of -18.44 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The company had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Sell-side analysts expect that Capricor Therapeutics Inc will post -1.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The shares were acquired at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now directly owns 7,090,351 shares in the company, valued at $38,004,281.36. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CAPR. Vanguard Group Inc. increased its holdings in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after purchasing an additional 200,499 shares during the period. Renaissance Technologies LLC grew its position in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares in the last quarter. Marshall Wace LLP acquired a new position in Capricor Therapeutics during the 2nd quarter valued at about $426,000. Bank of New York Mellon Corp raised its position in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics in the 2nd quarter worth approximately $147,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.